TY - JOUR
T1 - CSF microRNA Profiling in Alzheimer’s Disease: a Screening and Validation Study
AU - Dangla-Valls, Adrià
AU - Molinuevo, José Luis
AU - Altirriba, Jordi
AU - Sánchez-Valle, Raquel
AU - Alcolea, Daniel
AU - Fortea, Juan
AU - Rami, Lorena
AU - Balasa, Mircea
AU - Muñoz-García, Cristina
AU - Ezquerra, Mario
AU - Fernández-Santiago, Rubén
AU - Lleó, Alberto
AU - Lladó, Albert
AU - Antonell, Anna
PY - 2017/11/1
Y1 - 2017/11/1
N2 - © 2016, Springer Science+Business Media New York. MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression through post-transcriptional repression of target genes. They have been shown to be implicated in the pathophysiology of Alzheimer’s disease (AD) and proposed as disease biomarkers. In the present work, we have studied the expression levels of 754 miRNAs in cerebrospinal fluid (CSF) from AD patients and control subjects. We have explored a first screening cohort (N = 20) and selected 12 miRNAs to be further tested in a second independent validation cohort (N = 69). We have found a significant upregulation of miR-222 and miR-125b in AD CSF. Of these, the association of miR-222 with AD is novel and reported here for the first time whereas upregulation of miR-125b has been previously reported in AD brain. Yet we do not find association with other miRNAs which were previously linked to AD. Our results shed light on potential underlying pathophysiological processes of AD and also point out the need for consensus procedures in CSF miRNA detection and data analysis.
AB - © 2016, Springer Science+Business Media New York. MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression through post-transcriptional repression of target genes. They have been shown to be implicated in the pathophysiology of Alzheimer’s disease (AD) and proposed as disease biomarkers. In the present work, we have studied the expression levels of 754 miRNAs in cerebrospinal fluid (CSF) from AD patients and control subjects. We have explored a first screening cohort (N = 20) and selected 12 miRNAs to be further tested in a second independent validation cohort (N = 69). We have found a significant upregulation of miR-222 and miR-125b in AD CSF. Of these, the association of miR-222 with AD is novel and reported here for the first time whereas upregulation of miR-125b has been previously reported in AD brain. Yet we do not find association with other miRNAs which were previously linked to AD. Our results shed light on potential underlying pathophysiological processes of AD and also point out the need for consensus procedures in CSF miRNA detection and data analysis.
KW - Alzheimer’s disease
KW - Biomarkers
KW - Cerebrospinal fluid
KW - miR-125b
KW - miR-222
KW - microRNAs
U2 - 10.1007/s12035-016-0106-x
DO - 10.1007/s12035-016-0106-x
M3 - Article
SN - 0893-7648
VL - 54
SP - 6647
EP - 6654
JO - Molecular Neurobiology
JF - Molecular Neurobiology
IS - 9
ER -